![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, May 04, 2022 7:41:42 AM
What does momentum look like?
2015 study halts new screening of patients but continues enrollment and treatment and trial. Shorty stops at study halted (erroneous). Stock price pummeled.
2017 PFS trigger hit but study continues. 2017 Blinded, grouped data submitted for publication showing substantial increase in OS vs historical controls AND patients in screening all placed on treatment, no more placebo option. New patents. Shorty says they are hiding data. Stock price dropped after rally.
2018 OS trigger finally hit almost a year and a half after 2017 prediction, updated unblinded data presented showing improved long term survival vs 2017 data. New patents. Shorty says they did interim and study failed (erroneous), when will you learn. Company again declares no interim efficacy performed. Working towards data lock.
2019 company revises SAP and study endpoints to compare treated patients to contemporaneous pivotal trial controls and declares seeking approval for one and only one SAP to four regulators (US, EMA, UK, and Canada). Company changes Combo Checkpoint trial to Keytruda. Shorty says LP a criminal fleecing investors, doing it again with Advent. Stock price hits all time low.
2020 Uplist consultants added, Canada filing consultant hired full time, Flaskworks with automated manufacturing devices acquired. Database locked. PR says six step process ending in publication. LL presents Combination trial with Poly ICL shows improved efficacy. LL starts new Combo Checkpoint trial. EMA and UK post new SAP trial endpoints with contemporaneous control comparisons. Stock price rallies to $2.50. Shorty says fraud, never releasing data. Stock price falls.
2021 LP says six step process ending in publication. Company enters ‘Quiet Period’ LL presents all kinds of updated data including exciting prelim results with CI combo. Stock prices rallies to $2.15. Shorty say fraud, when will you learn. Stock price falls. Patents, patents, more patents. Company starts Premarket Promotion Campaign. UK manufacturing facility completed. UK manufacturing facility approved for production. Stock price flops.
2022 Manufacturing begins. UK treatment sites for specials expands throughout UK. UK continues treating GBM patients AND other cancers with DCVax in Specials Program. FDA publishes position statement in support of external control arm use in pivotal trials. LL provides more updates including new data triple Combo Trial and confirms new SAP accepted by FDA. More new Patents for Flaskworks and Combination with Checkpoint Inhibitors. Stock price rallies. Shorty says when will you learn, never releasing data. Stock rally continues. LL starts new speaking tour.
And we wait… Company purchases Exhibit Booth and Promotional Product Theater at ASCO. May is GBM awareness month. Longs say breakthrough data and global approvals coming soon
Shorty says when will you learn, they will never provide TLD.
Who do you believe?
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
FEATURED ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM